Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Tariff Resilience Score: 0/10 (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600613 Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613
42 GF Score
Price ¥11.61
GF Value ¥5.38
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Shanghai Shenqi Pharmaceutical Investment Management Co Tariff Resilience Score?

Shanghai Shenqi Pharmaceutical Investment Management Co has the Tariff Resilience Score of 0, which implies that the company might have .

Shanghai Shenqi Pharmaceutical Investment Management Co has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Shanghai Shenqi Pharmaceutical Investment Management Co might have .


Shanghai Shenqi Pharmaceutical Investment Management Co  (SHSE:600613) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Shanghai Shenqi Pharmaceutical Investment Management Co Tariff Resilience Score Related Terms

SHSE:600613
42GF Score
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be overvalued. The current stock price of ¥11.61 is trading 115.8% above its estimated GF Value™ of ¥5.38. GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Significantly Overvalued.

Key valuation signals for SHSE:600613:

  • Tariff Resilience Score: 0
  • GF Value™: ¥5.38 vs. price of ¥11.61 (115.8% above fair value)
  • GF Score™: 42/100 with 9 warning signs

No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Shenqi Pharmaceutical Investment Management Co Business Description

Other Exchanges 900904:China
Address 128 Weihai Road, Room 613, Changfa Building, Shanghai, CHN, 200003
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd is mainly engaged in pharmaceutical production and distribution in China.
42GF Score

Get the complete analysis for SHSE:600613

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.61
Price
¥5.38
GF Value